01 Radiopaque Closure Components Improve Device Visibility During FluoroscopyThe vascular closure devices market analysis shows a shift toward radiopaque markers that improve device visibility and placement accuracy during fluoroscopic arteriotomy closure. Boston Scientific filed a patent application for a vascular closure device with radiopaque components to improve imaging visibility during deployment. This innovation supports more precise vascular closure systems and complex femoral artery closure procedures.
02 Dual Action Closure Devices Combine Intraluminal and Extravascular SealingMedical device manufacturers are advancing dual action closure technologies that combine intraluminal anchoring with extravascular sealing to achieve effective arterial puncture closure. These designs integrate mechanical fixation with external sealing components to support controlled vascular access closure and reduce the risk of incomplete hemostasis. This innovation expands the design capabilities of arterial closure devices and creates new possibilities for advanced hemostasis devices and vascular closure technology.
01 The vascular closure devices market forecasts strategic investment activity driven by the expansion of arterial closure devices and femoral artery closure products. In January 2026, Haemonetics acquired Vivasure Medical in a deal valued at up to approximately USD 215 million. The acquisition strengthens its product portfolio through Vivasure's PerQseal Elite technology for sutureless arteriotomy closure in large-bore arterial and venous procedures.
01 TAVR Procedures Boost Large Bore Closure DemandThe wider use of transcatheter aortic valve replacement (TAVR) procedures increases demand for reliable closure of large femoral arterial access sites. Advanced suture mediated closure systems and plug-based closure technologies support effective hemostasis after catheter removal. This strengthens demand for large bore arterial closure devices and supports growth in the vascular closure devices market.
02 Mechanical Circulatory Support Expands Large Bore Closure DemandThe use of percutaneous mechanical circulatory support devices increases demand for reliable closure of large arterial access sites. Specialized femoral artery closure solutions support effective bleeding control and post procedure recovery. This expands the use of advanced vascular access closure technologies and large-bore hemostasis devices across complex cardiovascular procedures.
03 Impact Analysis of Key Drivers in Vascular Closure Devices MarketDriversMarket ImpactTAVR Procedures Boost Large Bore Closure DemandIncreases demand for reliable largen bore arterial closure devices.Same Day Discharge Boosts Rapid Hemostasis Device DemandSupports adoption of faster vascular access closure solutions.Mechanical Circulatory Support Expands Large Bore Closure DemandExpands demand for specialized femoral artery closure products.Endovascular Aneurysm Repair Supports Suture Mediated ClosureStrengthens demand for suture-mediated closure systems.Peripheral Arterial Interventions Expand Closure Device ApplicationsIncreases use of arteriotomy closure and collagen based devices.
01 Femoral Artery Calcification Complicates Device DeploymentSevere femoral artery calcification reduces vessel flexibility and complicates vascular closure devices deployment. It interfere with device anchoring, affect femoral artery closure, and increase the risk of incomplete hemostasis. These challenges limit the use of certain arterial closure devices and vascular closure systems in patients with complex vascular conditions.
02 Device Embolization Raises Safety ConcernsDisplacement of closure device components can cause vessel obstruction, reduced blood flow, and additional interventions. Improper deployment or unsuitable vascular anatomy increase these risks and raise concerns about vascular closure devices safety. Such complications reduce physician confidence and limit the adoption of certain vascular closure systems and vascular closure devices.
03 Impact Analysis of Key Restraints in Vascular Closure Devices MarketRestraintsMarket ImpactFemoral Artery Calcification Complicates Device DeploymentCalcification makes device placement difficult and limits product use.Device Embolization Raises Safety ConcernsDevice displacement increases complications and reduces physician confidence.Arterial Stenosis and Thrombosis Affect Device AcceptanceVessel narrowing and clot formation increase procedural risks.Arterial Variations Limit Device CompatibilityDifferences in vessel anatomy restrict device suitability.Limited Clinical Evidence Slows Adoption of New Closure MaterialsInsufficient safety data delays product acceptance and procurement.
01 Vascular Closure Devices for Percutaneous Embolization Procedures in Interventional Oncology Expand Market PotentialMedical device manufacturers target interventional oncology centers with specialized vascular closure devices and arterial closure devices for tumor embolization procedures. These products support reliable arteriotomy closure, effective hemostasis, and improved vascular access closure after catheter based interventions. Revenue opportunities include procedure specific vascular closure products, customized vascular closure solutions, and supply partnerships with hospitals, supporting growth in the vascular closure devices market.
02 Specialized Closure Products for Transcatheter Pulmonary Valve Implantation Create New Revenue OpportunitiesExpansion of structural heart and electrophysiology procedures increases demand for specialized vascular closure systems that support reliable access site closure and post-procedure hemostasis. Haemonetics received FDA approval for expanded labeling of its VASCADE MVP XL system to cover larger sheaths used in left atrial appendage closure (LAAC) and pulsed field ablation procedures. This expansion supports the use of advanced vascular closure devices across complex cardiac interventions and encourages manufacturers to develop procedure specific products for hospitals and cardiac centers.
October 2026 Haemonetics received U.S. FDA approval for its PerQseal Elite vascular closure device for large-bore arterial procedures using 14–22F sheaths.
September 2026 Abbott received an FDA PMA supplement approval for its Perclose ProGlide and Perclose ProStyle systems.
April 2026 Teleflex received FDA approval for a PMA supplement covering its MANTA vascular closure system.
March 2026 Cardiva Medical received FDA approval for a PMA supplement covering its VASCADE MVP XL venous vascular closure system.